IntegraGen's scientific advisory board for metastatic colorectal cancer includes world renown clinicians who represent both academic and community oncology. Our advisers provide us with valued insight and guidance on our efforts to develop oncology biomarkers which assist physicians to better manage cancer patients.
miR‐31‐3p and colorectal cancer
A molecular test for patients with metastatic colorectal cancer (mCRC) based on the miR-31-3p biomarker will allow for a more personalized approach to cancer care.
Studies demonstrating the association between miR-31-3p and survival in metastatic colorectal cancer have been published in peer-reviewed journals and presented at numerous scientific meetings.